Elocom

Leaflet attached to the packaging: information for the user

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Elocom, 1 mg/g (0.1%), ointment

Mometasone furoate

Read the leaflet carefully before using the medicine, as it contains important information for the patient.

• Keep this leaflet, so you can read it again if you need to.
• If you have any doubts, consult your doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Elocom and what is it used for
• 2. Important information before using Elocom
• 3. How to use Elocom
• 4. Possible side effects
• 5. How to store Elocom
• 6. Contents of the packaging and other information

1. What is Elocom and what is it used for

Elocom ointment contains the active substance mometasone furoate. Mometasone furoate is a synthetic corticosteroid with strong action; when used locally, it has anti-inflammatory, antipruritic, and vasoconstrictive effects. Elocom ointment is indicated for the relief of inflammatory and pruritic symptoms in corticosteroid-responsive skin diseases, such as psoriasis and atopic dermatitis.

2. Important information before using Elocom

When not to use Elocom:

• if the patient is allergic to mometasone furoate, other corticosteroids, or any of the other ingredients of this medicine (listed in section 6),
• in acne vulgaris,
• in rosacea,
• in skin atrophy,
• in perioral dermatitis,
• in bacterial infections (e.g., impetigo, pyoderma), viral infections (e.g., herpes simplex, chickenpox, and shingles, common warts, molluscum contagiosum), parasitic and fungal skin infections (e.g., caused by dermatophytes or yeasts),
• in post-vaccination reactions,
• in cutaneous tuberculosis,
• on syphilitic skin lesions,
• in anogenital pruritus,
• in diaper dermatitis,
• on damaged and ulcerated skin.

Warnings and precautions

Before starting to use Elocom, discuss it with your doctor or pharmacist. If symptoms of irritation or allergy occur after using the medicine, contact your doctor immediately. In the event of infections, the doctor will use appropriate antibacterial or antifungal treatment. If there is no rapid and positive response to treatment, discontinue the use of the corticosteroid until the infections are cured. Due to the increased risk of systemic side effects of corticosteroids, avoid using Elocom on large areas of the body, under dressings, for prolonged periods, and on the skin of the face and in skin folds, as well as in children. If it is necessary to apply the medicine to the face, treatment should not last more than 5 days. All side effects reported after using systemic corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children. In children, due to the greater ratio of body surface area to body mass than in adults, there is a greater likelihood of systemic side effects of corticosteroids, such as adrenal axis disorders and Cushing's syndrome. The medicine should not be used on skin covered with a diaper, as it may act like a dressing and increase the percutaneous absorption of mometasone furoate. Use the smallest effective dose of the medicine that allows for the relief of disease symptoms, especially in children. Long-term treatment with corticosteroids may disrupt the growth and development of children. Elocom is not intended for ophthalmic use (including the eyelids) due to the very rare risk of developing glaucoma or subcapsular cataract. Patients with psoriasis should use the medicine with special caution. Using the medicine in psoriasis may cause the disease to recur due to the development of tolerance, the occurrence of generalized pustular psoriasis, and general toxic effects related to skin continuity disorders. As with other potent topical corticosteroids, sudden discontinuation of treatment should be avoided. After sudden withdrawal of the medicine, severe redness, burning, and stinging (so-called "rebound effect") may occur. In such cases, consult your doctor. Elocom, like other medicines containing corticosteroids, may change the appearance of some skin lesions, making it difficult for the doctor to make a proper diagnosis, and may also delay healing. Consult your doctor, even if the above warnings refer to situations that have occurred in the past. If the patient experiences blurred vision or other vision disturbances, they should contact their doctor.

Elocom and other medicines

No data available. Tell your doctor or pharmacist about all medicines you are taking or have recently taken, as well as any medicines you plan to take.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before using this medicine.

Pregnancy

The safety of using Elocom during pregnancy has not been established. During pregnancy, Elocom can be used only when, in the doctor's opinion, the benefit to the mother outweighs the potential risk to the mother and fetus. However, the medicine should not be used on large areas of the body or for extended periods. Animal studies have shown that corticosteroids may harm the fetus.

Breastfeeding

It is not known whether topical corticosteroids are absorbed through the skin into the body to an extent that could pass into breast milk. The use of Elocom by breastfeeding women is possible only when the doctor decides to do so after careful consideration of the risk of side effects in children versus the benefits of treatment for the mother. If the doctor considers long-term therapy necessary, breastfeeding should be discontinued.

Driving and using machines

Elocom does not affect the ability to drive or use machines.

3. How to use Elocom

Always use this medicine exactly as your doctor has told you. If you are not sure, consult your doctor or pharmacist. Affected areas of the skin are usually smeared with a thin layer of ointment once a day. The use of ointment is recommended for the treatment of dry, scaly, and cracked lesions. If you feel that the effect of the medicine is too strong or too weak, consult your doctor.

Use in children

Elocom should be used with caution in children over 2 years of age, although the safety and efficacy of Elocom have not been studied for more than 3 weeks. There is insufficient data on the use of the medicine in children under 2 years of age. Use the smallest effective dose of the medicine that allows for the relief of disease symptoms. Long-term treatment with corticosteroids may disrupt the growth and development of children.

Using a higher dose of Elocom than recommended

No cases of overdose have been reported to date. Prolonged topical use of corticosteroids may lead to adrenal axis suppression and subsequent adrenal insufficiency. In the event of an overdose, the doctor will use appropriate symptomatic treatment and supportive therapy. Acute symptoms of corticosteroid overdose are usually reversible. In the case of chronic poisoning, the doctor will recommend gradual withdrawal of the medicine.

Missing a dose of Elocom

Do not use a double dose to make up for a missed dose.

4. Possible side effects

Like all medicines, Elocom can cause side effects, although not everybody gets them. The following side effects have been observed during the use of topical corticosteroids:

• Very rare (occurring in less than 1 in 10,000 patients): folliculitis, burning sensation, pruritus.
• Frequency not known (frequency cannot be estimated from the available data): infections, furuncles, paresthesia, contact dermatitis, hypopigmentation, hypertrichosis, striae, acneiform changes, skin atrophy, pain at the application site, application site reactions, blurred vision.

After using the medicine on a large area of skin for a long time, especially under occlusive dressings, systemic absorption of the medicine has been observed. The following side effects have been observed during the topical use of corticosteroids: dry skin, skin irritation, dermatitis, perioral dermatitis, skin maceration, folliculitis, and the occurrence of widened small blood vessels (telangiectasias).

Reporting side effects

If you experience any side effects, including any side effects not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Elocom

Keep the medicine out of the sight and reach of children. Do not store above 25°C. Do not use damaged or opened packaging. Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated. Shelf life after first opening the packaging: 4 weeks. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Elocom contains:

• The active substance of the medicine is mometasone furoate. Each gram of ointment contains 1 mg of mometasone furoate.
• The other ingredients are: hexylene glycol, purified water, diluted phosphoric acid, propylene glycol stearate, white wax, white petrolatum. This medicine contains 20 mg of propylene glycol stearate per gram of ointment, which corresponds to 400 mg of propylene glycol stearate per packaging (20 g tube).

What Elocom looks like and what the packaging contains

Elocom is an ointment. The packaging of the medicine is a tube containing 20 g of ointment, placed in a cardboard box. For more detailed information, please contact the marketing authorization holder or the parallel importer.

Marketing authorization holder in Belgium, the country of export:

Organon Belgium, Rue du Commerce 31, B-1000 Brussels, Belgium

Manufacturer:

NV Schering-Plough Labo, Industriepark 30, B-2220 Heist-op-den-Berg, Belgium

Parallel importer:

InPharm Sp. z o.o., ul. Strumykowa 28/11, 03-138 Warsaw

Repackaged by:

InPharm Sp. z o.o. Services sp. k., ul. Chełmżyńska 249, 04-458 Warsaw, Belgian marketing authorization number:BE163274

Parallel import authorization number: 361/22 Date of approval of the leaflet: 26.09.2022

[Information about the trademark]